Armistice Capital holds 8.9M shares in Travere Therapeutics as rare kidney disease stock climbs 110% following FILSPARI's ...

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to FILSPARI ...

A potential FDA approval for FILSPARI in FSGS by September 2025 could significantly expand its market reach, with the addressable patient population estimated at up to 30,000 in the U.S.

So far, Filspari’s launch has been going well. The drug brought in $27.1 million in sales in the second quarter of the year, coming 37% above the prior quarter and ahead of analysts’ consensus ...

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics ...

Learn about side effects, cost, uses, and more of Filspari (sparsentan), which is a prescription drug that helps manage IgA nephropathy in adults.

Since Filspari's trial data suggests it's superior to Irbesartan, its market might be larger in the long run. For context, Irbesartan's market is projected to grow to $2.9 billion by 2031.

FILSPARI should generally be avoided in patients with elevated aminotransferases (>3x ULN) at baseline because monitoring for hepatotoxicity may be more difficult and these patients may be at ...

FILSPARI should generally be avoided in patients with elevated aminotransferases (>3x ULN) at baseline because monitoring for hepatotoxicity may be more difficult and these patients may be at ...

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics ...

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Travere Therapeutics, Inc. (NASDAQ: TVTX) today ...